期刊文献+

兔VX2肝癌模型制作改良及影像学评价 被引量:5

Improvement in the preparation of rabbit models bearing VX2 liver tumor for interventional therapy study and imaging evaluation
下载PDF
导出
摘要 目的对兔VX2肝癌模型制作进行改良,以用于介入治疗学研究,同时探讨瘤灶的CT表现及CT在检测瘤灶中的作用。方法将VX2瘤细胞接种于兔皮下使其成瘤并传代;新西兰兔24只,以改良嵌插法建立移植性肝癌模型,于建模后7、14、21 d分别行超声、CT及血管造影检查,用于检测兔肝VX2瘤灶,评估瘤灶生长变化;随后处死动物,进行尸解,评估影像检查结果。结果 24只(100%)动物以改良嵌插法建立移植性肝癌模型全部成功。瘤灶以种植后2周CT显示最清楚和典型,直径1 cm^2 cm左右,平扫呈低密度或等密度,动脉早期明显强化,门脉期呈低密度,与周围肝组织分界较清楚。肝动脉造影显示肿瘤富血供。而种植后超过3周的肿瘤大部分发生坏死。结论嵌插改良法是一种值得推广的建立移植性肝癌模型的方法;在对瘤灶进行影像学评价上应尽量选择CT检查,接种后1周左右的瘤灶较小而难以观察;2周左右呈肝动脉源性血供丰富的约1 cm^2 cm的实体瘤,造影征像为肿瘤血管与肿瘤染色;3周以上瘤灶大多出现明显示坏死;因此对1~2cm大小的兔VX2肝癌瘤体,最适合行血管造影检查。 Objective To improve the preparation of rabbit models bearing VX2 hepatoma for interventional therapy study, and to investigate their CT features. Methods Eighty New Zealand white rabbits were implanted with VX2 hepatoma in the deep aspect of the left lobe of liver. CT scanning was performed in the experimental animals at 1 , 2 and 3 weeks after implantation. The plain, early arterial phase and portal phase images were obtained. Results Twenty-four (100%) rabbits were successfully implanted with VX2 hepatoma in the liver. On CT scans taken at 2 weeks after implantation, the tumors showed most clear and typical images: 1 -2 cm in diameter, hypodensity or isodensity on plain CT scans, markedly enhanced early arterial phase images, hypodensity on portal phase images, well discernible from the surrounding liver tissues. Hepatic angiography showed that the tumor was hypervascular. Necrosis was seen in most animals at 3 weeks after implantation. Conclusions The rabbit model bearing VX2 hepatoma is more suitable for interventional therapy study. CT is very useful in evaluating the tumors.
出处 《中国比较医学杂志》 CAS 2014年第2期29-32,共4页 Chinese Journal of Comparative Medicine
基金 山东省医学科学院资助项目(编号:200944)
关键词 VX2肿瘤 肝癌模型 CT 血管造影 VX2 hepatoma Liver cancer model Rabbit CT Angiography
  • 相关文献

参考文献7

二级参考文献79

  • 1周承凯,梁惠民,李欣,柳曦.实验兔VX2肝肿瘤模型制作及动脉插管技术探讨[J].介入放射学杂志,2006,15(2):101-104. 被引量:33
  • 2朱光宇,卢勤,滕皋军,魏晓莹,郭金和,余辉,邓钢,何仕诚,方文,李国昭.经导管动脉注入脂质体介导的p53基因治疗肝癌的实验研究[J].介入放射学杂志,2007,16(2):109-114. 被引量:14
  • 3钟灵,俞志坚,慕革非,全显跃.兔VX2肝癌模型的肝动脉插管技术改良及DSA表现[J].实用医学杂志,2007,23(12):1803-1805. 被引量:3
  • 4牛洪欣,何庆泗,魏冬,谭伟,高静.TK/GCV、CD/5-Fc系统对结肠癌肝转移抑制作用的实验研究[J].中国现代普通外科进展,2007,10(3):203-207. 被引量:5
  • 5Faivre S,Rarmond E,Boucher E,et al.Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma:an open-label,muhiceatre,phase Ⅱ study.Lancet Oncol,2009,10(8):794-800.
  • 6Uematsu S,Higashi T,Nouso K,et al.Altered expression of vascular endothelial growth factor,fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.J Gastroenterol Hepato1,2005,20(4):583-588.
  • 7Park JW,Finn RS,Kim JS,et al.Phase Ⅱ,open-label study of brivanib as first-line therapy in patients with advanced hepatocellulas carcinoma.Clin Cancer Res,2011,17(7):1973-1983.
  • 8Toh H,CP,Carr BI,Knox JJ,et al.A phase Ⅱ study of ABT869 in advanced hepatocellular carcinoma(HCC):Interim analysis.ASCO 2009,May 29 to June 2,2009,Orlando[C].Chicago:ASCO,2009.
  • 9Abou-Alfa GK,Johnson P,Knox JJ,et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial.JAMA,2010,304(19):2154-2160.
  • 10Yau T,CP,Cheung FY,Lee AS,et al.Phase Ⅱ trial of sorafenib with capecitabine and oxaliplatin(SECOX)in patients with locally advanced or metastatic hepatocellular carcinoma.Joint ECCO 15-34th ESMO Multidisciplinary Congress,Septmber 19-23,2009[C].Berlin:European Journal of Cancer Supplements,2009.

共引文献52

同被引文献69

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部